LEO Innovation Lab Announces Additions to Governing Advisory Board


COPENHAGEN, Denmark –  LEO Innovation Lab, the digital healthtech hub established by LEO Pharma to improve the lives of people living with a chronic skin conditions, announces that it will be adding two new international members to its governing advisory board: Joel Dudley, founding Director of the Institute for Next Generation Healthcare and Associate Professor of Genetics and Genomic Sciences at Mount Sinai, and Justin Ko, Director and Chief of Medical Dermatology for Stanford Health Care (SHC). The new governing board marks a new direction for LEO’s digital health arm to export it’s development at a global scale, and will be overseeing a roadmap of several new global product launches in 2019. 

In addition, LEO Innovation Lab will be saying farewell to Jakob Jønck, who, in the advent of a new funding round secured for his groundbreaking company, Simple Feast, will be departing to focus on growing the organization to the height of its potential. 

Dr. Dudley will contribute his expertise from running the Precision Health Enterprise at Mount Sinai hospital. He has extensive knowledge within next generation healthcare where digital solutions play a critical role. His guidance will enable LEO Innovation Lab to pioneer more disruptive developments in digital health technology. Dr. Dudley was one of the first scientists to work on the Apple Research platform. 

Dr. Ko joins LEO Innovation Lab from a background in melanoma and early cancer detection. At Stanford Health Care, he has led research initiatives around the application of machine learning and artificial intelligence to improve diagnosis and care delivery for melanoma patients. He has also developed a teledermatology care program, providing virtual visits for patients with skin conditions. 

Both Mount Sinai and Stanford Health care mark two of the most pioneering healthcare research institutions in the world. With the addition of two board members representing such institutions, LEO Innovation Lab’s development will by guided by globally renowned research, ensuring that its solutions will resonate beyond the Danish ecosystem.

LEO Innovation Lab has adopted a sharp focus on digital health as part of its mandate to improve lives for those living with chronic skin conditions. As digital platforms such as smartphone apps and telemedicine become increasingly ubiquitous in the lives of patients, both expectations and demands places on the healthcare infrastructure are rapidly evolving. Discovering ways to help shape this digital ecosystem for patients has therefore become central to the question of healthcare delivery, and LEO Innovation Lab is working with a wide range of technological developments to service this, as well as leading technology partners all over the world. 

In advising and steering developments around AI and diagnosis at LEO Innovation Lab, Dr. Dudley and Dr. Ko will work closely alongside existing board members Gitte Aabo (CEO and President, LEO Pharma), Kim Kjoeller (Executive Vice President Research and Development, LEO Pharma) and Mette Vestergaard (Executive Vice President Global People and Communications, LEO Pharma). 

“LEO Innovation Lab is an organization that is standing at the cusp of driving real change in the way patients can access healthcare, with new technologies that are shaping the next generation of healthcare delivery,’ said Dr. Dudley. “It is truly an honour to be invited to be Board Member. It is my hope that I can help enable an increased access to more accurate diagnosis, and more effective treatment plans for conditions such as psoriasis and atopic dermatitis, through steering the development of projects that have already demonstrated themselves as truly remarkable.”

“I see great potential in LEO Innovation Lab’s current research within the application of machine learning and artificial intelligence to improve diagnosis and treatment of skin conditions,” said Dr. Ko. “The possible applications of machine learning in healthcare are vast, and even the most advanced research has only scratched the surface. It’s exciting to be part of an organization that is daring to break new ground in this field, at an unprecedented speed of development, and I am honoured to be guiding it.” 

LEO Innovation Lab will draw on the expertise of its advisory board to focus on two key strategies. These efforts will be closely aligned with Dr. Dudley and Dr. Ko’s direction:

  •  AI-assisted diagnosis through imaging technology – The area is an innovative arm of healthcare that leverages machine-learning and computer vision technology to diagnose an image. LEO Innovation Lab is working to hone this technology to enhance the efficiency and time-pressure on dermatologists, and provide patients with access to healthcare irrespective of location or income.
  • Digitalizing clinical trials – By building platforms that automate clinical trial recruitment and qualification process for clinical trials, LEO Innovation Lab aims to enable more trials to finish in shorter time frames, and bring new treatments to the patient faster. 

“Working closely with both Dr. Dudley and Dr. Ko will allow LEO Innovation Lab to bring our solutions more closely integrated to the ecosystem of patients,” said Kristian Hart-Hansen, CEO, LEO Innovation Lab. “We are at a point where we have several mature technologies that are ready to be accepted into the healthcare infrastructure, and are eager to start making a difference. I am confident that having direction from such esteemed experts, and their unrivalled knowledge of the field can enable us to achieve this.”